Seres Therapeutics Inc.

Seres Therapeutics, Inc. is a clinical‑stage microbiome biotech focused on oral live biotherapeutics. Its pipeline includes Phase III SER‑109 for C. difficile and Phase IIb SER‑287 for ulcerative colitis, targeting high‑need gastrointestinal infections.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 103
HQ: Cambridge

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
MCRB	Seres Therapeutics Inc. Cap: 0.1B \| P/E: 17.8	EQUITY	NMS	USD	US81750R1023	Active	📈